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1078–5884/00Results from the Prospective Registry of Endovascular
Treatment of Abdominal Aortic Aneurysms (RETA): Mid
Term Results to Five YearsS.M. Thomas,* J.D. Beard, M. Ireland and S. Ayers
on Behalf of the Vascular Society of Great Britain and Ireland and the
British Society of Interventional RadiologySheffield Vascular Institute, Northern General Hospital, Herries Road, Sheffield S5 7AU, UKObjectives. To assess the mid-term outcomes up to 5 years following endovascular repair of abdominal aortic aneurysms
(EVAR), following its initial introduction into practice in the UK.
Design. A prospective voluntary Registry of Endovascular Treatment of Aneurysms (RETA) collected demographic and risk
factor data, short term (30 day) outcomes and follow up outcomes up to 5 years from the 41 centres that initially undertook
EVAR in the UK.
Results. Short term outcomes (30 days): 90.4% of aneurysms were successfully excluded, 6.1% had persistent endoleaks
and 5.8% of patients had died. Follow up was obtained from 30 days up to 5 years (mean 3.1 years). Returns rates for
requested follow up data were 87% at 1 year and 77, 65, 52 and 51% at 2, 3, 4 and 5 years, respectively. Ninety percent of
deaths at follow up were unrelated to the stent-graft or aneurysm. Persistent proximal type I endoleak was associated with
significant mortality both from attempted open repair or from rupture if untreated. Other endoleaks were more benign.
Complications related to the aneurysm or device occurred at an average rate of 15% per annum. The most common
complications were secondary endoleaks or graft migration. Endovascular treatment was preferred if treatment was
necessary for graft complications. The cumulative freedom from secondary procedure (Kaplan–Meier) were 87, 77, 70, 65
and 62% at 1, 2, 3, 4 and 5 years of follow up, respectively.
Conclusions. Registry data provides useful information to guide the design of more formal trials. Collecting follow up from
voluntarily submitted data is difficult. The registry data remains well ahead of the trial data, but indicate that long term
follow up is required in these trials, because of the high rate of complications seen at follow up.Keywords: EVAR; Endovascular aneurysm repair; Stent-grafting.Introduction
The Registry for Endovascular Treatment of Aneurysms
(RETA) was established to collect data on endovascular
abdominal aortic aneurysm repair (EVAR) from UK
centres as this new approach to treating abdominal
aortic aneurysm (AAA) was introduced into UK
practice. Since, its inception on the 1st of January 19961
a total of 1823 cases have been submitted to the Registry.
One thousand cases were submitted to the Registry prior
to the introduction of the UK randomized trials (EVAR 1
and 2) in 2000. The majority of EVARs were subse-
quently performed within these trials. Cases submitted
to RETA after this time were performed outside the trial,ing author. Steven Thomas, MRCP, FRCR, MSc, Senior
cular Radiology, Sheffield Vascular Institute, Vascular
, Northern General Hospital, Sheffield S5 7AU, UK.
: s.m.thomas@sheffield.ac.uk
0563 + 08 $35.00/0 q 2005 Elsevier Ltd. All rights reserusually early in a centre’s experience, to allow entry into
the trials. As a result the RETA dataset became less
representative of current UK practice. The main value of
the Registry then became the collection of long-term
outcome for those cases treated early in UK practice.
This paper presents data for the first 1000 cases
submitted to the Registry, and though major short-
term outcomes are briefly presented, these do not
differ greatly from results published previously on a
smaller cohort.1 The focus of this paper is on mid-term
EVAR durability and patient outcome.Methodology
Details of the Registry, submitting centres and datasets
are discussed in the previous paper.1 A simple one-
page follow-up form was sent out to the each centre onEur J Vasc Endovasc Surg 29, 563–570 (2005)
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by post, fax or via e-mail. Original submission of data
was voluntary, and return of follow up data was
dependent on the submitting centre in the majority of
cases. Centres that failed to return forms were sent a
further form, followed by a telephone reminder. The
returned follow up data was manually entered into an
Access database.
Statistical analysis was performed using the SPSSw
for Windowse statistical software. The analysis that is
presented divides patients into subgroups defined by
stent-graft type, fitness for open repair and aneurysm
diameter. Stent-graft type were divided into the aorto-
uni-iliac stent-graft with a crossover graft (AUIC) and
the aortic tube or bifurcated stent-graft (AT/BI).
Patients corresponding to the American Society of
Anaesthesiology (ASA) grade I–III were deemed ‘fit’
for open repair and those corresponding to ASA IV–V
were deemed ‘unfit’. Patients with hostile abdomens
or other contraindications to open repair, but ASA I–III
were, included in the ‘fit’ group. Subgroups of ‘small’
AAA !6 cm diameter and ‘large’ AAA O6 cm were
analysed separately.
Statistical testing used Chi-squared test of indepen-
dence (for categorical data) and t-tests (for continuous
data) to assess differences in baseline data. Logistic
regression was used to compare differences in out-
comes adjusting for available confounders for defined
subgroups. The variables used in the logistic
regression model were: fitness for repair, indication
for repair, age, device type and aneurysm diameter.
Results are presented as odds ratios (OR). These
represent the increased (or decreased) odds (with
95% confidence intervals) of an outcome in the first
compared to the second group. Kaplan–Meier analysis
was used for the analysis of long-term outcomes.Patient Demographics
One thousand cases were submitted to the Registry
from 41 centres between 1st January 1996 and March
3rd 2000. The number of cases per centre ranged from
2 to 143 (median 16). The number of centres and cases
increased each year until the EVAR trial began. The
indication for repair was elective asymptomatic
abdominal aortic aneurysm (AAA) in 83.2%, elective
symptomatic in 13.5%, acute non-rupture in 1.6% and
stable rupture in 1.4%.
Overall, 3.2% of patients received an AT, 26.3% an
AUIC and 70.2% a BI (missing data nZ3). There were
relatively few ATs in the Registry and their use fell out
of favour in the first 2 years because of distal
endoleaks. AUICs built ‘in-house’ were theEur J Vasc Endovasc Surg Vol 29, June 2005commonest stent-graft used at the beginning of the
Registry but these have now been superseded by
commercially available and CE marked devices. The
devices used are detailed in Table 1. The increase in the
proportion of BI stent-grafts is also reflected in the fact
that more than 60% of endovascular repairs were
performed in the operating theatre when the Registry
commenced, but by 1998 more than 60% were
undertaken in the radiology suite. The proportion of
patients having the procedure under loco-regional
anaesthesia also increased.
The median aneurysm diameter was 6 cm (range
2.5–15) with a median infra-renal neck length of
2.4 cm. Overall 42% were classified as large (O6 cm).
There were significantly more large aneurysms in the
AUIC group (132/253, 52.3%) compared to the AT/BI
group (288/735, 39.7%), OR 1.65, 95% CI 1.24–2.2, p!
0.001. Patients with larger aneurysms were also more
unfit (95/559, 17% vs 125/420, 29.8%, OR 2.1, 95% CI
1.5–2.8, p!0.001).
A total of 22.7% patients were considered unfit for
open repair (missing data nZ3). Of the fit patients, 67
(8.8%) were considered fit but unsuitable for open
repair. There was a significantly higher proportion of
unfit patients in the AUIC group (96/263, 36.5%)
compared to the AT/BI group (130/174, 17.7%). The
increased odds of being unfit in the AUIC group was
2.67 (95% CI 1.95–3.65, p!0.001).
The median age of the patients was 73 years (range
44–93) with a male: female ratio of 9:1. There was no
difference in age (72 vs 73 years) between those treated
with an AUIC and those treated with an AT/BI,
respectively. Nor was there any difference in age
between fit and unfit patients (72 vs 72 years).Short Term Results
Overall, 77.2% of endovascular repairs resulted in
successful exclusion of the aneurysm, without com-
plications, by the end of the procedure (missing data
nZ4). The success rate was the same for both stent-
graft types (Table 2). Additional endovascular pro-
cedures were required significantly more often in the
AT/BI group (pZ0.003). However, conversion to open
repair occurred more frequently in the AUIC group
(pZ0.001). The overall conversion rate was 3.3% but
this fell significantly from 13/143 (9.1%) in 1996 to 1/
335 (0.3%) in 1999 (pZ0.002) (Fig. 1). Mortality
following immediate conversion was 30%, but rose
to 66.7% for unfit patients.
Post-procedure complications within 30 days
occurred in 27.8% of cases (Table 3). There were
significantly more complications in the AUIC group
Table 1. Endoprosthesis type
Device Number (%)
Ancure (Guidant EVT Europe) 60 (6)
AneurX (Medtronic) 254 (25.4)
Bard device (Bard UK) 11 (1.1)
Baxter device (Baxter) 1 (0.1)
Excluder (Gore) 19 (1.9)
Gianturco-Dacron (‘Home made’) 123 (12.3)
Gianturco-PTFE (‘Home made’) 17 (1.7)
Hol B Endostent 1 (0.1)
Ivanchev-Malmo (‘Home made’) 2 (0.2)
Palmaz/PTFE (‘Home made’) 64 (6.4)
Stenford (Stenford, France) 2 (0.2)
Talent (Medtronic) 117 (11.7)
Vanguard (Boston Scientific) 174 (17.4)
Zenith (Cook, UK) 144 (14.4)
Missing 11 (1.1)
Total 1000 (100)
RETA: Mid Term Results 565(pZ0.006). At 30 days, 90.4% of aneurysms had been
successfully excluded, 6.1% had persistent endoleaks
and 5.8% of patients had died. There were significantly
more deaths in the AUIC group, (33/263, 12.5% vs 24/
726, 3.3%, OR 2.6, 95% CI 1.4–4.8, pZ0.001). There
were also significantly more deaths in unfit patients
(33/223, 14.8% vs 25/769, 3.3%, OR 3, 95% CI 1.6–5.5,
pZ0.001). The higher mortality rate in the AUIC group
remained significant even after adjusting for available
confounding influences such as the higher proportion
of unfit patients within this subgroup (Fig. 2). The
mortality rate halved from 15/143 (10.5%) in 1996 to
15/335 (4.5%) in 1999 but this failed to achieve
significance (Fig. 1). The mortality rate in women
(5.7%) was significantly higher than men (1.9%) (pZ
0.01). Persistent endoleaks and mortality were signifi-
cantly higher in those with larger aneurysms (p!
0.0001 and pZ0.0046, respectively). The median length
of stay was longer for patients in the AUIC group
(mean 8 vs 5 days, pZ0.001 after adjusting for
confounders).Fate of Primary Endoleaks
Endoleaks2 were identified in 146 cases either duringTable 2. Immediate outcomes
Characteristics All AT/BI
Aneurysm
excluded
769/996 (77%) 566/733 (77%)
Additional endo-
vascular procedures
110/996 (11%) 94/733 (13%)
Additional endo-
vascular procedures
52/996 (5%) 40/733 (6%)
Conversion to open
repair
33/996 (3%) 13/733 (2%)
AT/BI, aortic tube and bi-iliac devices; AUI, aorto-uni-iliac devices; ane
of procedure.the primary procedure or at 30 day follow up.
Proximal anastomotic (PA) type I endoleaks2 at the
end of the primary procedure were the most common
reported and occurred in 54 cases (Fig. 3). Most (51/
54) were identified immediately post-procedure and
three at imaging at 30 days follow up. Most had urgent
treatment, either immediately the endoleak was
identified or within a few days. Of these 54 endoleaks,
11 were converted to open repair immediately (three
deaths) and two were converted later (both survived).
Six had operative banding, but this was only success-
ful in two cases (three deaths). Proximal cuffs were
successful in 11/12 cases (one death at 3 months due to
rupture from a persistent leak). In three patients a
second stent-graft repaired the leak and PTA was
successful in 2/3 cases. Sixteen patients had no
immediate treatment and three died of rupture at 10
days, 16 days and 4 months. Overall 19 patients had a
persistent PA endoleak, with or without treatment and
4 (21%) subsequently died of rupture within 1 year.
Operative repair was attempted in 20 cases, resulting
in six deaths (mortality rate 30%).
Collateral (type II) endoleaks3 were the next most
common endoleak reported and occurred in 44 cases
(35 visible immediately and nine within 30 days).
Twenty-three of these had occluded spontaneously by
30 days. At 1 year, four of the remaining patients had
been successfully treated by embolisation or laparo-
scopic clipping and 11 had spontaneously occluded.
Only two cases had persistent endoleak at 1 year. No
follow up was available for three cases. One patient
with an apparently sealed collateral endoleak and an
excluded aneurysm on follow up CT died of AAA
rupture 10 months post-procedure.
Distal anastomotic (DA) type I endoleaks at the end
of the primary procedure occurred in 19 cases (14
detected immediately and five within 30 days). Of
these, seven spontaneously sealed by imaging at 30
days, one was embolised and three had extension
stent-grafts placed prior to discharge. Of the seven
persistent DA endoleaks, three were treated within 1
year and remained excluded at follow up or death.AUIC OR (95% CI) p value
203/263 (77%) 1.1 (0.8–1.6) 0.5
16/263 (6%) 0.4 (0.2–0.7) 0.003
12/263 (4%) 0.7 (0.3–1.4) 0.3
20/263 (8%) 5.0 (2.3–10.8) 0.0001
urysm exclusion, no flow into aneurysm sac angiographically at end
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Fig. 1. Fall in 30 day conversion and mortality rates by year. The conversion rate fell significantly from 13/143 (9.1%) in 1996
to 1/335 (0.3%) in 1999 (pZ0.002). The mortality halved from 15/143 (10.5%) in 1996 to 15/335 (4.5%) in 1999, but this did not
achieve significance.
S. M. Thomas et al.566Four cases had open repair (OR) because of persistent
or recurrent DA endoleak (one death at OR). There
were no rupture-related deaths in this group at follow
up.
Occluder endoleaks occurred in four cases. Two had
occluded spontaneously within 30 days, one was
successfully surgically banded and the other success-
fully embolised. There were no ruptures reported for
these cases.
Midgraft (type III) endoleaks occurred in 15 cases.
Fourteen were excluded at available follow up with no
treatment. One case required a further stent-graft for
fabric tear, with no recurrence at follow up. The site of
endoleak was stated on the registry form for 10 cases.
There were no ruptures reported at follow up in these
patients.Mid-term Results
At the time of data analysis 90% of cases had reached
the 4 year follow up point and 55% had reached the 5
year follow up point, giving a mean follow up of 3.1
years (range 30 days–5 years) Despite the best efforts
of the Registry co-ordinator voluntary data sub-
mission resulted in returns rates for requested followTable 3. In-hospital complications
Characteristics All AT/BI
Any complication 272/976 (28%) 175/716 (24%
Technical complication 55/976 (6%) 31/716 (4%)
Wound complication 78/976 (8%) 55/716 (8%)
Renal failure 40/976 (4%) 21/716 (3%)
Colonic ischaemia 6/976 (0.6%) 4/716 (0.6%)
Other medical complications 147/976 (15%) 92/716 (13%)
AT/BI, aortic tube and bi-iliac devices; AUI, aorto-uni-iliac devices.
Eur J Vasc Endovasc Surg Vol 29, June 2005up data of 87% at 1 year and 77, 65, 52 and 51% at 2, 3, 4
and 5 years, respectively.
Mortality in the first year post-procedure was 11%.
Most deaths (90% nZ82) were due to co-morbid
conditions, the most common being cardiac-respirat-
ory disease or malignancy, i.e. unrelated to graft
complications. Six deaths were related to AAA
rupture, three of these were detailed above as they
had primary proximal type I endoleaks. One other had
a secondary DA type I endoleak, the other two cases
had apparently excluded aneurysms at follow up CT
scanning. In subsequent years the mortality rates were
10, 7, 10 and 8%, at 2, 3, 4 and 5 years post-procedure,
respectively. As previously most deaths were not
related to graft complications, though five other fatal
ruptures were reported, one other patient ruptured
with an associated secondary proximal endoleak, and
survived open repair, one patient died following
surgery for secondary endoleak and two patients
died as a result of overwhelming sepsis and infected
stent-grafts. The cumulative risk of rupture (Kaplan–
Meier) was 2% at the 5 year follow up point.
Overall 253 complications related to the device or
aneurysm were reported, occurring in 13, 14, 15, 16
and 16% at 1, 2, 3, 4 and 5 year follow up intervals,
respectively. Fifty-four percent (nZ139) of these wereAUIC OR (95% CI) p value
) 97/268 (37%) 1.57 (1.1–2.1) 0.006
24/268 (9%) 2.1 (1.2–3.7) 0.013
23/268 (9%) 1.1 (0.6–1.8) 0.84
19/268 (7%) 2.1 (1.1–4.2) 0.03
2/268 (0.8%) 1.1 (0.2–6.7) 0.9
55/268 (21%) 1.5 (1.01–2.2) 0.045
Fig. 2. Comparison of 30 day mortality rates for patients deemed fit or unfit for open repair, by graft type (AUIC vs AT/BI).
There were significantly more deaths in unfit patients (33/223, 14.8% vs 25/769, 3.3%, OR 4.9, 95% CI 2–12, p!0.001). The
higher mortality rate in the AUIC group remained significant after adjusting for the higher proportion of unfit patients.
RETA: Mid Term Results 567secondary endoleaks or graft migration, with second-
ary collateral (type II) endoleak the most common
problem reported. Many collateral endoleaks were not
treated, but other types of endoleak and proximal graft
migration were usually treated using endovascular
techniques, such as embolisation or further stent-
grafts. Graft or limb occlusions and/or kinks were the
next most common problem accounting for 18% (nZ
45) of device or AAA complications. Limb or graft
occlusion often required a surgical bypass procedure.
Increasing size of the sac remnant with no endoleak
was also reported in a number of cases, and though
most cases were kept under close observation conver-
sion to OR was reported in 25% (nZ5/20) of cases.
Overall open repair was reported for 23 cases to treat
complications, though it was unclear from submitted
registry forms if all cases were formal late conversions
to repair the abdominal aortic aneurysm or more
limited surgical procedures to deal with a specific graftFig. 3. Fate of primary proximalor limb complication. During later years of follow up
graft distortion and suture breaks were widely
reported, though most did not required treatment as
they were not necessarily associated with endoleak or
graft migration.
Follow up of secondary complications and their
treatment showed that on average 39% (nZ65) of
reported complications persisted, with a third of these
having some form of intervention for the complication
and a further 3% (nZ7) had recurrence of the original
complication requiring further treatment. As a result,
for those patients treated for secondary complications
only an average of 33% (nZ57) survived with no
further problems.
Using Kaplan–Meier analysis the cumulative free-
dom from endoleak was 88, 80, 76, 71 and 68% and the
cumulative freedom from secondary procedure rates
were 87, 77, 70, 65 and 62% at 1, 2, 3, 4 and 5 years of
follow up, respectively (Fig. 4).anastomotic type I endoleaks.
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The overall short term outcome results for EVAR from
RETA show a 30 day mortality of 5.8%, which is not
clearly better than that reported for open repair.
However, the data represents an early experience.
Nearly 25% of patients were considered unfit for open
repair and another 25% received AUIC stent-grafts
that were fabricated in-house, due to an initial lack of
commercially available alternatives. The mortality rate
of a group more comparable to those being offered
open repair, i.e. fit patients treated with AT/BI stent-
grafts, was 1.7%, and this is very similar to the early
results of the EVAR and DREAM trials which reported
procedure related mortality of 1.4 and 1.7%, respect-
ively in patients who were fit for open repair and
randomised to EVAR.4,5 The fall in conversion rates
and mortality with time reflects advances in stent-graft
design, better patient selection and improved mentor-
ing of new centres.
RETA shows that larger aneurysms have worse 30
day outcomes with fewer large aneurysms excluded
and a higher mortality. This is important, particularly
for unfit patients who tend to present when their
aneurysms are larger. This may be related to these
aneurysms being more technically challenging,
though there was no increase in the rate of technical
complications in larger aneurysms, but there was a
trend towards an increased need for conversion to
open repair. It may be that the larger aneurysms had
wider necks and available stent-grafts were under-
sized, but these data were not collected in the Registry.
It is recognised that AUIC devices can be used to
treat a larger proportion of aneurysms6 and we have
shown that those treated with it tend to be older, more
unfit and to have larger aneurysms. Comparisons withFig. 4. Cumulative freedom from endoleak obtained using
Kaplan–Meier analysis.
Eur J Vasc Endovasc Surg Vol 29, June 2005the AT/BI group remain difficult in the context of a
registry because these differences confound direct
comparison of the two groups. Conversions to open
repair and technical complications were more frequent
in the AUIC group and even after adjustment for
available confounding influences the morbidity and
mortality rates were higher for those treated with
AUIC devices. Also, after adjustment, patients treated
with an AUIC device had a significantly longer
hospital stay. This is probably related to the surgical
crossover graft that is required for this type of device.
The mortality rate post-procedure was about 10%
per annum, fairly typical for patients with arterial
disease. Most deaths at follow up were unrelated to
stent-graft complications, mostly due to cardiac dis-
ease or malignancy. Between 30 days and 1 year, six
ruptures (1%) were reported. Of these, three had
primary proximal type I endoleaks that had persisted
despite attempts at endovascular treatment and one
had a documented secondary endoleaks. The annual
rupture rate was about 1% per year in the first couple
of years post-procedure, giving a cumulative risk of
rupture of 2% at 5 years post-procedure. All but one
rupture was fatal, and proximal type I endoleaks, if not
corrected, were particularly associated with a poor
outcome, emphasising the need to correct these
endoleaks whenever possible. It should be noted that
two deaths were attributed to systemic sepsis thought
to be secondary to stent-graft infection. With the move
towards deployment of stent-grafts in the radiology or
endovascular suites, this underlines the importance of
theatre-quality asepsis in these environments.
There was an overall primary endoleak rate of over
14% (146 endoleaks). Of these the most common were
endoleaks from the proximal anastomosis or from
collaterals. Of the 19 persistent proximal endoleaks at
30 days 21% lead to AAA rupture during follow up.
This appears to justify an aggressive approach to
treatment of type I proximal anastomotic endoleaks,
when they occur. However, surgical treatment of this
group of patients resulted in perioperative mortality in
30%, and the mortality rate of converting patients
deemed unfit was 66.7%. This suggests that unfit
patients must be counselled about the poor chances of
survival should endovascular repair fail and conver-
sion become necessary. This mortality from conversion
to open repair is higher than that reported in other
series.7 Patients did better if an endovascular treat-
ment, such as cuffing was feasible, but if conversion is
necessary, and it can be deferred for a few days, such
an approach seems sensible to allow recovery from the
primary procedure and related nephrotoxicity, but
undue delay should be avoided. Other primary
endoleaks had a more benign course with a reasonable
RETA: Mid Term Results 569chance of sealing spontaneously, though one patient
with an apparently sealed collateral (type II) endoleak
and an excluded aneurysm at follow up died of AAA
rupture 10 months post-procedure. Similarly the
Eurostar Registry has found that rupture can occur
with no obvious endoleak or complication,8 and this
probably accounts for the conversion to OR of five
cases in RETA with increasing size of the AAA sac, but
no identifiable endoleak. The Eurostar Registry has
also found associations between collateral endoleaks
and continued aneurysm expansion, and the risk of
rupture with an increasing size of the AAA sac.9 More
frequent surveillance and/or intervention is, there-
fore, warranted in such cases.
Most of the uncertainty surrounding EVAR relates
to the long term complications of the procedure. It is,
therefore, vital that the durability of the devices and
the long-term outcomes of these cases are subjected to
rigorous assessment. In this cohort, reported compli-
cations related to the aneurysm or device occurred at
an average rate of 15% per annum. These data are
similar to results for early generation devices from the
Eurostar Registry.10 Many of these complications were
secondary endoleaks, and often these could be treated
using endovascular techniques. However, follow-up
of these secondary problems suggest that many recur
or persist, and only about 30% of patients survive with
no further problems. Therefore, although most com-
plications can be treated successfully, continued long-
term surveillance is required. The cost of this
surveillance, and subsequent treatment, may out-
weigh the short-term benefits of EVAR, but only a
long term cost analysis as part of the EVAR trials
would confirm this. Also, a large proportion of the
stent-grafts in the Registry were first generation
devices that were fabricated in-house or second-
generation devices that have been withdrawn due to
failure of structural integrity, or superseded by devices
with improvements in design. It remains to be seen
whether third-generation devices suffer from the same
problems. The initial data suggests that they may be
better in this respect.11,12
As a first step registries can be of value in the
assessment of new treatments. Regulatory organis-
ations such as the UK National Institute for Clinical
Excellence (NICE) will often accept that, in the absence
of formal trials, registries can act as a means of
assessment of new treatments or technologies. In the
case of EVAR, NICE specifically recommends that all
patients undergoing EVAR should either be treated as
part of a randomised trial or entered into a registry.13
However, it is important to understand the limitations
of Registry data. The only way to eliminate confound-
ing and obtain clear results when comparinginterventions is to use randomisation. Data sub-
mission to registries is usually voluntary which risks
bias in the data submitted. Furthermore follow-up
data becomes increasingly difficult to obtain. Despite
the best efforts of the Registry co-ordinator the returns
rates we present in this paper fell from 87% at 1 year to
51% at 5 years. It is very difficult to ensure data is
submitted and it is not possible to make this
compulsory. If a large amount of data is submitted it
is likely to be representative of practice at the time it is
collected, but the results presented can only ever
represent the best estimates within the limitations of
the data collected. In the case of RETA this cohort of
cases represents the early experience in the UK with
early device designs, with problems of incomplete
data follow up.
However, if these problems are borne in mind then
registry data can provide useful insight into the results
of new treatments, and can be used in planning trials
and to generate hypotheses to be tested. Indeed,
results from RETA were used in the planning of the
EVAR trials and as an audit tool to assess centres for
trial entry. The outcomes from the randomised trials
will provide more definitive results of EVAR in fit and
unfit patients. However, continued follow-up of the
1000 patients within the RETA cohort remains vital.
The duration of follow-up is a long way ahead of the
randomised trials and highlight the potential pro-
blems that occur long term, as well as providing a
benchmark to show changes in outcome over time.
The collection and analysis of data from this and
similar registries should facilitate the early identifi-
cation, quantification and correction of device-related
problems.Key Messages† Short term outcomes (30 days): 90.4% of aneurysms
were successfully excluded, 6.1% had persistent
endoleaks and 5.8% had died.† Conversion rates and mortality fell with time
reflecting better patient selection, advances in
stent-graft design, and improved mentoring of
new centres.† A higher mortality rate in the AUIC group
remained significant after adjusting for the higher
proportion of unfit patients.† Most deaths at follow up were unrelated to the
stent-graft or aneurysm. Persistent proximal endo-
leak was associated with significant mortality both
from attempted open repair or from rupture if
untreated.† Complications related to the aneurysm or deviceEur J Vasc Endovasc Surg Vol 29, June 2005
S. M. Thomas et al.570
Euoccurred at a rate of approximately 15% per annum.
Many of these complications were secondary
endoleaks, many of which could be successfully
treated by endovascular means.† Long term costs of stent-graft surveillance, and
secondary treatment, may outweigh the short-term
benefits of EVAR.† Voluntary Registries complement, but do not
replace, Randomised Controlled Trials.† Data collection for voluntary registries is proble-
matic, with achieved returns rates for requested
follow up data of 87% at 1 year and 77, 65, 52 and
51% at 2, 3, 4 and 5 years, respectively.Acknowledgements
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